Data from the CANTOS trial lend some support to this line of thinking as it was observed that anti-inflammatory therapy among individuals with elevated CRP and prevalent CVD resulted in reduced risk of cardiovascular as well as lung cancer events.15,16 Our current study highlights that baseline CRP levels as well as longitudinal increases in CRP over time in community-dwelling adults are associated with increased cardiovascular and cancer risk. The gene discussed is CRP; the disease is lung cancer.